Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders

J Ciron; B Audoin; B Bourre; D Brassat; F Durand-Dubief; D Laplaud; E Maillart; C Papeix; S Vukusic; H Zephir; R Marignier; N Collongues; NOMADMUS group, under the aegis of OFSEP, SFSEP

doi:10.1016/j.neurol.2017.11.005

Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders

Rev Neurol (Paris). 2018 Apr;174(4):255-264. doi: 10.1016/j.neurol.2017.11.005. Epub 2018 Mar 30.

Authors

J Ciron¹, B Audoin², B Bourre³, D Brassat⁴, F Durand-Dubief⁵, D Laplaud⁶, E Maillart⁷, C Papeix⁷, S Vukusic⁸, H Zephir⁹, R Marignier¹⁰, N Collongues¹¹; NOMADMUS group, under the aegis of OFSEP, SFSEP

Affiliations

¹ Pôle de neurosciences, department of neurology, hôpital Pierre-Paul-Riquet, university hospital of Toulouse, place du Dr-Baylac, 31059 Toulouse Cedex 9, France; Pôle neurosciences locomoteur, department of neurology, university hospital of Poitiers, 2, rue de la Milétrie, 86021 Poitiers Cedex, France. Electronic address: ciron.j@chu-toulouse.fr.
² Pôle de neurosciences cliniques, department of beurology, hôpital de la Timone, AP-HM, 13005 Marseille, France; CNRS, CRMBM UMR 7339, Aix-Marseille University, 13005 Marseille, France.
³ Department of neurology, university hospital of Rouen, 76000 Rouen, France.
⁴ Pôle de neurosciences, department of neurology, hôpital Pierre-Paul-Riquet, university hospital of Toulouse, place du Dr-Baylac, 31059 Toulouse Cedex 9, France; UMR 1043, University Toulouse III, 31400 Toulouse, France.
⁵ Department of neurology, Sclérose en Plaques, pathologies de la myéline et neuro-inflammation, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, 69677 Lyon, France.
⁶ Department of neurology, university hospital of Nantes, 44093 Nantes, France.
⁷ Department of neurology, Pitié-Salpêtrière Hospital, AP-HP, 75013 Paris, France.
⁸ Department of neurology, Sclérose en Plaques, pathologies de la myéline et neuro-inflammation, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, 69677 Lyon, France; Inserm U1028 CNRS UMR 5292, Observatoire français de la Sclérose en Plaques, centre des neurosciences de Lyon, 69003 Lyon, France; University Lyon 1, 69003 Lyon, France.
⁹ Department of neurology, university hospital of Lille, 59037 Lille, France.
¹⁰ Department of neurology, Sclérose en Plaques, pathologies de la myéline et neuro-inflammation, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, 69677 Lyon, France; Inserm U1028 CNRS UMR 5292, FLUID Team, faculté de médecine Laennec, centre de recherche en neurosciences de Lyon, 69008 Lyon, France.
¹¹ Department of neurology, university hospital of Strasbourg, 67200 Strasbourg, France; Clinical Investigation Center, Inserm U1434, university hospital of Strasbourg, 67200 Strasbourg, France; Biopathology of Myelin, neuroprotection and therapeutic Strategies, Inserm U1119, university hospital of Strasbourg, 67200 Strasbourg, France.

PMID: 29606320
DOI: 10.1016/j.neurol.2017.11.005

Abstract

There is growing evidence of a preventive effect of Rituximab (RTX) in neuromyelitis optica spectrum disorders (NMO-SD). This monoclonal antibody against CD20 is becoming the most widely used preventive therapy in NMO-SD, as a first-line therapy or as a rescue therapy. Nevertheless, considerable heterogeneity still exists concerning the pre-treatment work-up, the vaccinations required before and under treatment, the number and dosage of infusions, prevention of the risk of infusion-related reactions, prevention of infections under treatment, and frequency of therapeutic cycles. Thanks to a collaborative work among NMO-SD experts belonging to the NOMADMUS project, we provide here recommendations for all these topics concerning RTX use in NMO-SD.

Keywords: Guidelines; Neuromyelitis optica; Recommendations; Rituximab; Treatment.

Publication types

Practice Guideline
Review

MeSH terms

Antibodies, Monoclonal / therapeutic use
Humans
Neuromyelitis Optica / diagnosis
Neuromyelitis Optica / drug therapy*
Practice Guidelines as Topic
Rituximab / administration & dosage
Rituximab / therapeutic use*

Substances

Antibodies, Monoclonal
Rituximab